Epygen Biotech India and Dyadic USA: Epygen Biotech Gets Funding From Govt For New Affordable Covid Vaccine /business/epygen-biotech-gets-funding-from-govt-for-new-affordable-covid-vaccine-news-191120?utm_source=amp&utm_medium=tw&utm_campaign=amp
Epygen Biotech India and Dyadic USA: Epygen Biotech Gets Funding From Govt For New Affordable Covid Vaccine /business/epygen-biotech-gets-funding-from-govt-for-new-affordable-covid-vaccine-news-191120?utm_source=amp&utm_medium=tw&utm_campaign=amp
Epygen Biotech India and Dyadic USA: Epygen Biotech Gets Funding From Govt For New Affordable Covid Vaccine /business/epygen-biotech-gets-funding-from-govt-for-new-affordable-covid-vaccine-news-191120?utm_source=amp&utm_medium=tw&utm_campaign=amp
As per CDC Interim Clinical Considerations for Vaccine use, "vaccination of persons with known current SARS-CoV-2 infection should be deferred until the person has recovered". RT-PCR with nearly 100% accuracy, should be used to test candidates prior to vaccination for safety.
If 2 billion doses are to be produced quickly in the region with or without minor changes in the spike protein’s receptor binding domain, only this technology can deliver such quantities.
Epygen India and Dyadic USA is using C1 technology to express unprecedented amounts of antigen proteins, so that a SARS COV-2 VARIANT Vaccine can made available within INR 50 per dose. The Animal Trials at Israel are extremely promising.